{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:42:51Z","timestamp":1790206971658,"version":"4.1.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Congenital hyperinsulinism (CHI) is the commonest cause of persistent hypoglycaemia in neonates and infants (blood glucose &amp;lt;3.0\u00a0mmol\/L in first 2\u20133\u00a0days of life; &amp;lt;3.5\u00a0mmol\/L after 3 days of life). Diazoxide demonstrates variable efficacy depending on the underlying genetic variant and clinical phenotype. Diazoxide has been associated with side effects that are likely dose dependent. This narrative review synthesizes current evidence on diazoxide\u2019s pharmacokinetics and side effect profile to support the development of individualised dosing strategies guided by genotype and patient-specific risk factors, with the aim of optimizing therapeutic outcomes and minimizing adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>A structured PubMed search was performed to review diazoxide use in hyperinsulinism (HI). Articles not involving neonatal HI, not specifying diazoxide dosing or focusing on alternative therapies were excluded. Addition articles were identified through reference screening or hand searched.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Traditional diazoxide dosing (5\u201315\u00a0mg\/kg\/day) is being challenged by emerging evidence supporting the benefits of lower starting doses (2\u20135\u00a0mg\/kg\/day), particularly in neonates with transient HI or specific genetic variants such as\n                      <jats:italic>HNF1A<\/jats:italic>\n                      and\n                      <jats:italic>HNF4A<\/jats:italic>\n                      . Lower starting doses in selected CHI patients have been shown to achieve adequate glycaemic control with fewer complications, including pulmonary hypertension (PH) and fluid retention. Diazoxide-responsiveness correlates strongly with the underlying molecular etiology.\n                      <jats:italic>ABCC8<\/jats:italic>\n                      and\n                      <jats:italic>KCNJ11<\/jats:italic>\n                      gene mutations often predict diazoxide-unresponsiveness, whereas\n                      <jats:italic>GLUD1<\/jats:italic>\n                      ,\n                      <jats:italic>HADH<\/jats:italic>\n                      , and other variants typically predict responsiveness. Early predictors of unresponsiveness include large for gestational age (LGA) status (unrelated to maternal diabetes), early neonatal onset, and the need for high glucose infusion rates (GIR). Risk factors for adverse effects include renal impairment, prematurity, and low albumin levels, which may increase free diazoxide concentrations and drug toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Individualized dosing based on clinical phenotype and genotype can improve safety and effectiveness in CHI management. Lower initial doses are recommended in patients with propensity for diazoxide sensitivity or risk factors for adverse events, while more rapid escalation may be warranted in suspected diazoxide-resistant cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1781424","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T05:27:39Z","timestamp":1774848459000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["From standard to individualized diazoxide therapy in congenital hyperinsulinism: a narrative review"],"prefix":"10.3389","volume":"17","author":[{"given":"Teresa","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, KK Women\u2019s and Children\u2019s Hospital","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Chan","sequence":"additional","affiliation":[{"name":"Endocrinology Service, KK Women\u2019s and Children\u2019s Hospital","place":["Singapore, Singapore"]},{"name":"Paediatrics Academic Clinical Program, DukeNUS Medical School","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherie","family":"Chua","sequence":"additional","affiliation":[{"name":"Endocrinology Service, KK Women\u2019s and Children\u2019s Hospital","place":["Singapore, Singapore"]},{"name":"Paediatrics Academic Clinical Program, DukeNUS Medical School","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Cher","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, KK Women\u2019s and Children\u2019s Hospital","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, KK Women\u2019s and Children\u2019s Hospital","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Chandran","sequence":"additional","affiliation":[{"name":"Paediatrics Academic Clinical Program, DukeNUS Medical School","place":["Singapore, Singapore"]},{"name":"Department of Neonatology, KK Women\u2019s and Children\u2019s Hospital","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Yap","sequence":"additional","affiliation":[{"name":"Endocrinology Service, KK Women\u2019s and Children\u2019s Hospital","place":["Singapore, Singapore"]},{"name":"Paediatrics Academic Clinical Program, DukeNUS Medical School","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780198840787.001.0001","volume-title":"Neonatal formulary | Drug use in pregnancy and the first year of life","author":"Ainsworth","year":"2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1687-9856-2014-24","article-title":"Congenital hyperinsulinism: clinical and molecular characterisation of compound heterozygous ABCC8 mutation responsive to diazoxide therapy","volume":"2014","author":"Arya","year":"2014","journal-title":"Int. J. Pediatr. Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1530\/EDM-19-0013","article-title":"Exceptional diazoxide sensitivity in hyperinsulinaemic hypoglycaemia due to a novel HNF4A mutation","volume":"2019","author":"Arya","year":"2019","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/dme.13823","article-title":"Therapies and outcomes of congenital hyperinsulinism-induced hypoglycaemia","volume":"36","author":"Banerjee","year":"2019","journal-title":"Diabet. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.21037\/pm-22-11","article-title":"Pharmacokinetics of drugs: newborn perspective","volume":"7","author":"Bansal","year":"2023","journal-title":"Pediatr. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/jmg.2009.075416","article-title":"ABCC8 and KCNJ11 molecular spectrum of 109 patients with diazoxide-unresponsive congenital hyperinsulinism","volume":"47","author":"Bellann\u00e9-Chantelot","year":"2010","journal-title":"J. Med. Genet."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa543","article-title":"Management and appropriate use of diazoxide in infants and children with hyperinsulinism","volume":"105","author":"Brar","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/archdischild-2021-322845","article-title":"Safety and efficacy of low-dose diazoxide in small-for-gestational-age infants with hyperinsulinaemic hypoglycaemia","volume":"107","author":"Chandran","year":"2022","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1163591","DOI":"10.3389\/fendo.2023.1163591","article-title":"Watchful waiting versus pharmacological management of small-for-gestational-age infants with hyperinsulinemic hypoglycemia","volume":"14","author":"Chandran","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1471596","DOI":"10.3389\/fendo.2024.1471596","article-title":"Case report: a novel HNF1A variant linked to gestational diabetes, congenital hyperinsulinism, and diazoxide hypersensitivity","volume":"15","author":"Chandran","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1102307","DOI":"10.3389\/fendo.2022.1102307","article-title":"Phosphomannomutase 2 hyperinsulinemia: recent advances of genetic pathogenesis, diagnosis, and management","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/cen.14096","article-title":"Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: recommendations from a multicentre study in the United Kingdom","volume":"91","author":"Chen","year":"2019","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0246463","DOI":"10.1371\/journal.pone.0246463","article-title":"Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2021","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.pharmthera.2013.06.007","article-title":"Multiplicity of effectors of the cardioprotective agent, diazoxide","volume":"140","author":"Coetzee","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/genes11040450","article-title":"The potential role of activating the ATP-Sensitive potassium channel in the treatment of hyperphagic obesity","volume":"11","author":"Cowen","year":"2020","journal-title":"Genes (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00431-019-03544-z","article-title":"Higher C-peptide levels and glucose requirements may identify neonates with transient hyperinsulinism hypoglycemia who will benefit from diazoxide treatment","volume":"179","author":"Davidov","year":"2020","journal-title":"Eur. J. Pediatr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000531766","article-title":"International guidelines for the diagnosis and management of hyperinsulinism","volume":"97","author":"De Leon","year":"2024","journal-title":"Horm. Res. Paediatr."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4172\/2161-0665.1000149","article-title":"Intractable feeding intolerance and abdominal distention in a preterm infant: an unusual side effect of diazoxide","volume":"3","author":"De\u011firmencio\u011flu","year":"2013","journal-title":"Pediatr. and Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4274\/jcrpe.2017.S007","article-title":"Congenital hyperinsulinism: diagnosis and treatment update","volume":"9","author":"Demirbilek","year":"2017","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1530\/EJE-14-0045","article-title":"Clinical characteristics and phenotype-genotype analysis in Turkish patients with congenital hyperinsulinism; predominance of recessive KATP channel mutations","volume":"170","author":"Demirbilek","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13633-017-0048-8","article-title":"Diagnosis and treatment of hyperinsulinaemic hypoglycaemia and its implications for paediatric endocrinology","volume":"2017","author":"Demirbilek","year":"2017","journal-title":"Int. J. Pediatr. Endocrinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/nmo.12337","article-title":"Diminished vagal tone is a predictive biomarker of necrotizing enterocolitis-risk in preterm infants","volume":"26","author":"Doheny","year":"2014","journal-title":"Neurogastroenterol. Motil."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1435","DOI":"10.1055\/s-0043-1764385","article-title":"Pulmonary hypertension and necrotizing enterocolitis in neonates treated with diazoxide","volume":"41","author":"Duggal","year":"2024","journal-title":"Am. J. Perinatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000511139","article-title":"Clinical predictors of transient versus persistent neonatal hyperinsulinism","volume":"93","author":"Falzone","year":"2020","journal-title":"Horm. Res. Paediatr."},{"key":"B25","unstructured":"FDA drug safety communication: FDA warns about a serious lung condition in infants and newborns treated with proglycem (diazoxide)\n          \n          \n          2015"},{"key":"B26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1210\/jc.2016-3164","article-title":"Novel hypoglycemia phenotype in congenital hyperinsulinism due to dominant mutations of uncoupling protein 2","volume":"102","author":"Ferrara","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B27","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1530\/EJE-09-0861","article-title":"Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations","volume":"162","author":"Flanagan","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/pedi.12512","article-title":"A CACNA1D mutation in a patient with persistent hyperinsulinaemic hypoglycaemia, heart defects, and severe hypotonia","volume":"18","author":"Flanagan","year":"2017","journal-title":"Pediatr. Diabetes"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0164577","DOI":"10.1371\/journal.pone.0164577","article-title":"Stability of diazoxide in extemporaneously compounded oral suspensions","volume":"11","author":"Friciu","year":"2016","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fendo.2019.00111","article-title":"The genetic and molecular mechanisms of congenital hyperinsulinism","volume":"10","author":"Galcheva","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/pedi.12254","article-title":"Congenital hyperinsulinism in Chinese patients: 5-yr treatment outcome of 95 clinical cases with genetic analysis of 55 cases","volume":"17","author":"Gong","year":"2016","journal-title":"Pediatr. Diabetes"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/s41372-018-0218-4","article-title":"Prevalence and safety of diazoxide in the neonatal intensive care unit","volume":"38","author":"Gray","year":"2018","journal-title":"J. Perinatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s11154-020-09548-7","article-title":"Hyperinsulinemic hypoglycemia in children and adolescents: recent advances in understanding of pathophysiology and management","volume":"21","author":"G\u03cbemes","year":"2020","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2174\/092986706775527947","article-title":"Towards selective Kir6.2\/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives","volume":"13","author":"Hansen","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1210\/jc.2018-01613","article-title":"Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide","volume":"103","author":"Herrera","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B37","doi-asserted-by":"publisher","first-page":"873254","DOI":"10.3389\/fendo.2022.873254","article-title":"Congenital hyperinsulinism: current laboratory-based approaches to the genetic diagnosis of a heterogeneous disease","volume":"13","author":"Hewat","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1165\/rcmb.2009-0017OC","article-title":"Effects of mitochondrial potassium channel and membrane potential on hypoxic human pulmonary artery smooth muscle cells","volume":"42","author":"Hu","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1515\/jpem-2012-0224","article-title":"The treatment effect of diazoxide on 44 patients with congenital hyperinsulinism","volume":"25","author":"Hu","year":"2012","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"B40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1530\/EJE-12-0673","article-title":"Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism","volume":"168","author":"Kapoor","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e20193202","DOI":"10.1542\/peds.2019-3202","article-title":"Necrotizing enterocolitis in neonates with hyperinsulinemic hypoglycemia treated with diazoxide","volume":"147","author":"Keyes","year":"2021","journal-title":"Pediatrics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0221615","DOI":"10.1371\/journal.pone.0221615","article-title":"A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome","volume":"14","author":"Kimonis","year":"2019","journal-title":"PLoS One"},{"key":"B43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000478696","article-title":"Population pharmacokinetics of diazoxide in children with hyperinsulinemic hypoglycemia","volume":"88","author":"Kizu","year":"2017","journal-title":"Horm. Res. Paediatr."},{"key":"B44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/DHPS.S198255","article-title":"Pulmonary hypertension occurring with diazoxide use in a preterm infant with hypoglycemia","volume":"11","author":"Kylat","year":"2019","journal-title":"Drug Healthc. Patient Saf."},{"key":"B45","volume-title":"Diazoxide","year":"2025"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2337\/db10-1631","article-title":"Diazoxide-unresponsive congenital hyperinsulinism in children with dominant mutations of the \u03b2-cell sulfonylurea receptor SUR1","volume":"60","author":"Macmullen","year":"2011","journal-title":"Diabetes"},{"key":"B47","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/cen.14987","article-title":"Low-dose diazoxide is safe and effective in infants with transient hyperinsulinism","volume":"100","author":"Malhotra","year":"2024","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/01.res.87.10.873","article-title":"C-terminal tails of sulfonylurea receptors control ADP-induced activation and diazoxide modulation of ATP-sensitive K(+) channels","volume":"87","author":"Matsuoka","year":"2000","journal-title":"Circ. Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/B978-0-323-03961-1.50087-8","article-title":"Chapter 84 - Vasodilators","author":"McInnes","year":"2007","journal-title":"Compr. Hypertens."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1210\/clinem\/dgad014","article-title":"Diazoxide choline extended-release tablet in people with Prader-Willi Syndrome: a double-blind, placebo-controlled trial","volume":"108","author":"Miller","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B52","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4274\/jcrpe.821","article-title":"Hyperinsulinaemic hypoglycaemia:genetic mechanisms, diagnosis and management","volume":"4","author":"Mohamed","year":"2012","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.mehy.2015.08.025","article-title":"Topical sulfonylurea as a novel therapy for hypertrichosis secondary to diazoxide, and potentially for other conditions with excess hair growth","volume":"85","author":"Newfield","year":"2015","journal-title":"Med. Hypotheses"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/children10010005","article-title":"Diazoxide for neonatal hyperinsulinemic hypoglycemia and pulmonary hypertension","volume":"10","author":"Newman-Lindsay","year":"2022","journal-title":"Child. (Basel)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/cen.14991","article-title":"Low-dose diazoxide therapy in hyperinsulinaemic hypoglycaemia","volume":"100","author":"Ng","year":"2024","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nature04711","article-title":"KATP channels as molecular sensors of cellular metabolism","volume":"440","author":"Nichols","year":"2006","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/bcp.12741","article-title":"Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future","volume":"80","author":"O'Hara","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1536\/ihj.20-024","article-title":"Pulmonary hypertension following increased dosing of diazoxide in an infant","volume":"61","author":"Ohnishi","year":"2020","journal-title":"Int. Heart J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2337\/diabetes.52.1.199","article-title":"Physical exercise-induced hyperinsulinemic hypoglycemia is an autosomal-dominant trait characterized by abnormal pyruvate-induced insulin release","volume":"52","author":"Otonkoski","year":"2003","journal-title":"Diabetes"},{"key":"B60","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1530\/EJE-11-0160","article-title":"Characterization of ABCC8 and KCNJ11 gene mutations and phenotypes in Korean patients with congenital hyperinsulinism","volume":"164","author":"Park","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"876903","DOI":"10.3389\/fendo.2022.876903","article-title":"Global registries in congenital hyperinsulinism","volume":"13","author":"Pasquini","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1628125","DOI":"10.3389\/fendo.2025.1628125","article-title":"Real-world experience with the use of diazoxide among people living with congenital hyperinsulinism and their caregivers","volume":"16","author":"Pasquini","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2165\/00003088-197702030-00004","article-title":"Pharmacokinetics and response to diazoxide in renal failure","volume":"2","author":"Pearson","year":"1977","journal-title":"Clin. Pharmacokinet."},{"key":"B64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2125.1976.tb00585.x","article-title":"Renal function, protein binding and pharmacological response to diazoxide","volume":"3","author":"Pearson","year":"1976","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B65","first-page":"23","article-title":"Management of neonatal hyperinsulinemic hypoglycemia: trends over nine years","volume":"108","author":"Pillai","year":"2025","journal-title":"R. I. Med. J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1136\/archdischild-2020-319057","article-title":"Necrotising enterocolitis in newborns receiving diazoxide","volume":"106","author":"Prado","year":"2021","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"B67","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/cpt197314173","article-title":"Disposition of diazoxide in children","volume":"14","author":"Pruitt","year":"1973","journal-title":"Clin. Pharmacol. Ther."},{"key":"B68","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0022-3565(25)29746-4","article-title":"Metabolism of diazoxide in man and experimental animals","volume":"188","author":"Pruitt","year":"1974","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B69","unstructured":"Diazoxide\n          \n          \n          2026"},{"key":"B70","doi-asserted-by":"publisher","first-page":"494","DOI":"10.5056\/jnm15061","article-title":"Targeting ion channels: an important therapeutic implication in gastrointestinal dysmotility in patients with spinal cord injury","volume":"21","author":"Radulovic","year":"2015","journal-title":"J. Neurogastroenterol. Motil."},{"key":"B72","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ad.2012.03.012","article-title":"Acquired generalized hypertrichosis due to diazoxide","volume":"104","author":"Salido","year":"2013","journal-title":"Actas Dermosifiliogr."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1056\/NEJM196911202812102","article-title":"Protein binding and vascular activity of diazoxide","volume":"281","author":"Sellers","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1231043","DOI":"10.3389\/fendo.2023.1231043","article-title":"Standardised practices in the networked management of congenital hyperinsulinism: a UK national collaborative consensus","volume":"14","author":"Shaikh","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s13312-022-2438-0","article-title":"Molecular characterization and management of congenital hyperinsulinism: a tertiary centre experience","volume":"59","author":"Sharma","year":"2022","journal-title":"Indian Pediatr."},{"key":"B76","doi-asserted-by":"publisher","first-page":"E355","DOI":"10.1210\/jc.2012-2169","article-title":"Genotype and phenotype correlations in 417 children with congenital hyperinsulinism","volume":"98","author":"Snider","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B77","article-title":"VYKAT\u2122 XR (diazoxide choline) extended-release tablet","volume-title":"Accessdata FDA","author":"Soleno Therapeutics","year":"2025"},{"key":"B78","doi-asserted-by":"publisher","first-page":"E2026","DOI":"10.1210\/jc.2012-1356","article-title":"Novel presentations of congenital hyperinsulinism due to mutations in the MODY genes: HNF1A and HNF4A","volume":"97","author":"Stanescu","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B79","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1210\/jc.2015-3651","article-title":"Perspective on the genetics and diagnosis of congenital hyperinsulinism disorders","volume":"101","author":"Stanley","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B80","doi-asserted-by":"publisher","first-page":"51s","DOI":"10.2967\/jnumed.120.246033","article-title":"(18)F-6-Fluoro-l-Dopa PET\/CT imaging of congenital hyperinsulinism","volume":"62","author":"States","year":"2021","journal-title":"J. Nucl. Med."},{"key":"B81","article-title":"PROGLYCEM\u00ae (diazoxide) oral suspension","volume-title":"Accessdata FDA","year":"2024"},{"key":"B82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000497458","article-title":"Rate of serious adverse events associated with diazoxide treatment of patients with hyperinsulinism","volume":"91","author":"Thornton","year":"2019","journal-title":"Horm. Res. Paediatr."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231222","article-title":"Thrombocytopaenia: a serious side effect of diazoxide","volume":"12","author":"Thus","year":"2019","journal-title":"BMJ Case Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00246-017-1652-3","article-title":"Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review","volume":"38","author":"Timlin","year":"2017","journal-title":"Pediatr. Cardiol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2333794x17703462","DOI":"10.1177\/2333794X17703462","article-title":"A novel intragenic SLC16A1 mutation associated with congenital hyperinsulinism","volume":"4","author":"Tosur","year":"2017","journal-title":"Glob. Pediatr. Health"},{"key":"B86","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0923-1811(90)90130-6","article-title":"The effects of topical diazoxide on hair follicular growth and physiology of the stumptailed macaque","volume":"1","author":"Uno","year":"1990","journal-title":"J. Dermatol Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1210\/jc.2017-02157","article-title":"Congenital hyperinsulinism and hypopituitarism attributable to a mutation in FOXA2","volume":"103","author":"Vajravelu","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B88","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4183\/aeb.2021.383","article-title":"Diazoxide-induced neutropenia and long-term Follow-up in a patient with hyperinsulinemia-hyperammonemia due to GLUD1 mutation","volume":"17","author":"Vuralli","year":"2021","journal-title":"Acta Endocrinol. (Buchar)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/j.1464-5491.2007.02285.x","article-title":"Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy","volume":"24","author":"Wabitsch","year":"2007","journal-title":"Diabet. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13023-015-0367-x","article-title":"Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers","volume":"10","author":"Welters","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4274\/jcrpe.galenos.2019.2019.0046","article-title":"Clinical management and gene mutation analysis of children with congenital hyperinsulinism in south China","volume":"11","author":"Xu","year":"2019","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00431-003-1328-2","article-title":"Severe transient hyperinsulinaemic hypoglycaemia: two neonates without predisposing factors and a review of the literature","volume":"163","author":"Yap","year":"2004","journal-title":"Eur. J. Pediatr."},{"key":"B93","doi-asserted-by":"publisher","first-page":"E141","DOI":"10.1210\/jc.2010-1281","article-title":"Molecular and clinical analysis of Japanese patients with persistent congenital hyperinsulinism: predominance of paternally inherited monoallelic mutations in the KATP channel genes","volume":"96","author":"Yorifuji","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B94","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1297\/cpe.26.127","article-title":"Clinical practice guidelines for congenital hyperinsulinism","volume":"26","author":"Yorifuji","year":"2017","journal-title":"Clin. Pediatr. Endocrinol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000356772","article-title":"High prevalence of severe circulatory complications with diazoxide in premature infants","volume":"105","author":"Yoshida","year":"2014","journal-title":"Neonatology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1161\/01.cir.98.14.1400","article-title":"Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension","volume":"98","author":"Yuan","year":"1998","journal-title":"Circulation"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1013874","DOI":"10.3389\/fendo.2023.1013874","article-title":"Syndromic forms of congenital hyperinsulinism","volume":"14","author":"Zenker","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B98","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0022-3565(25)20288-9","article-title":"Characterization of sulfonylurea receptors and the action of potassium channel openers on cholinergic neurotransmission in Guinea pig isolated small intestine","volume":"259","author":"Zini","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1781424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T05:27:43Z","timestamp":1774848463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1781424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":96,"alternative-id":["10.3389\/fphar.2026.1781424"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1781424","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"article-number":"1781424"}}